Has the Abbott Laboratories Sell-Off Finally Created an Entry Point?

Whether Abbott Laboratories (NYSE: ABT) banal is astatine a bully introduction constituent depends connected your concern skyline and tolerance for near-term uncertainty. The banal has been punished hard successful 2026, and the question is whether that punishment has overshot the fundamentals.

Abbott Labs is simply a diversified healthcare elephantine spanning aesculapian devices, diagnostics, nutrition, and established pharmaceuticals. Its $168 cardinal marketplace headdress reflects decades of compounding, but the banal has unwound gains implicit the past year. A $21 cardinal acquisition of Exact Sciences, completed successful March, added crab diagnostics brands Cologuard and Cancerguard portion introducing integration costs and EPS dilution the marketplace is inactive digesting.

Abbott delivered a cleanable bushed successful its astir caller quarter. Net income reached $11.164 billion, up 7.78% year-over-year, portion adjusted diluted EPS came successful astatine $1.15, extending a four-quarter streak of beating EPS estimates. Medical Devices led with $5.539 cardinal successful revenue, up 13.2%, anchored by FreeStyle Libre CGM income of $2.080 billion, up 7.5%.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

The Exact Sciences woody positions Abbott arsenic a person successful oncology diagnostics, a fast-growing marketplace with important underpenetration. CEO Robert Ford called it "another high-growth concern to the Abbott portfolio, further strengthening our assurance successful delivering accelerating maturation arsenic we determination done the year." Full-year guidance calls for comparable income maturation of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58. Abbott has besides declared its 409th consecutive quarterly dividend of $0.63 per share, its 54th consecutive twelvemonth of dividend increases, a way grounds fewer companies match.

The banal fell astir 4.7% connected the time of the Q1 net beat, adjacent arsenic the broader marketplace rose. That absorption signals existent concern. The Exact Sciences acquisition volition dilute 2026 EPS by astir $0.20 per share, and the nutrition conception posted a 6% gross diminution successful Q1, with pediatric nutrition down 8.5%.

NEC babe look litigation adds quantifiable risk. An Illinois assemblage awarded $70 cardinal successful damages to 4 families alleging Abbott's Similac Special Care 24 look caused necrotizing enterocolitis successful premature infants. Abbott is appealing, but much cases are pending. Combined with operating income declining 20.32% year-over-year owed to acquisition costs, the near-term net representation is cloudy.